Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

860 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions.
Campbell AR, Duggan MC, Suarez-Kelly LP, Bhave N, Opheim KS, McMichael EL, Trikha P, Parihar R, Luedke E, Lewis A, Yung B, Lee R, Raulet D, Tridandapani S, Groh V, Yu L, Yildiz V, Byrd JC, Caligiuri MA, Carson WE 3rd. Campbell AR, et al. Among authors: byrd jc. Cancer Immunol Res. 2017 Sep;5(9):778-789. doi: 10.1158/2326-6066.CIR-16-0005. Epub 2017 Jul 19. Cancer Immunol Res. 2017. PMID: 28724544 Free PMC article.
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P. Eisenbeis CF, et al. Among authors: byrd jc. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6101-10. doi: 10.1158/1078-0432.CCR-04-0525. Clin Cancer Res. 2004. PMID: 15447996 Clinical Trial.
FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways.
Ganesan LP, Joshi T, Fang H, Kutala VK, Roda J, Trotta R, Lehman A, Kuppusamy P, Byrd JC, Carson WE, Caligiuri MA, Tridandapani S. Ganesan LP, et al. Among authors: byrd jc. Blood. 2006 Jul 15;108(2):718-25. doi: 10.1182/blood-2005-09-3889. Epub 2006 Mar 16. Blood. 2006. PMID: 16543474 Free PMC article.
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA. Khan KD, et al. Among authors: byrd jc. Clin Cancer Res. 2006 Dec 1;12(23):7046-53. doi: 10.1158/1078-0432.CCR-06-1571. Clin Cancer Res. 2006. PMID: 17145827 Clinical Trial.
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. Zhao X, et al. Among authors: byrd jc. Blood. 2007 Oct 1;110(7):2569-77. doi: 10.1182/blood-2006-12-062927. Epub 2007 Apr 17. Blood. 2007. PMID: 17440052 Free PMC article.
860 results